Phase 4 Type 2 Diabetes Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged between 18 and 70 years old
- People who have been clinically diagnosed with type 2 diabetes
- People whose glycosylated hemoglobin (a measure of blood sugar control over time) is between 6.5% and 9.5%
- People who have either taken no diabetes medication, or only one oral diabetes tablet, in the past 6 months
- People whose fasting blood sugar level is below 13.9 mmol/L (if taking no medication) or below 13.3 mmol/L (if taking medication)
- People whose diabetes medication dose and type have remained unchanged for the past 3 months (if medication is being taken)
- People with a Body Mass Index (BMI) of 45 or below
- People who are willing and able to sign a consent form agreeing to take part
Who may not be able to join:
- People who have type 1 diabetes
- People who have serious diabetes-related complications such as diabetic ketoacidosis, hyperosmolar state, or lactic acidosis
- People who have a known allergy to the study drug
- People with abnormal liver or kidney function test results, as defined by specific laboratory thresholds (confirm with trial site)
- People who have another serious illness affecting major organs
- People who have had a heart attack, unstable chest pain, stroke, mini-stroke, or serious heart failure requiring hospitalisation within the past 6 months
- People who have certain heart rhythm problems, specifically Mobitz Type II second- or third-degree heart block, or sick sinus syndrome, unless a pacemaker has been fitted (confirm with trial site)
- People whose baseline heart rhythm measurement (QT interval) is above a certain length — above 450ms for males or above 460ms for females (confirm with trial site)
- People who are currently taking certain heart rhythm medications known as Class IA or Class III antiarrhythmic drugs
- People who currently have a systemic infection of any kind, including bacterial, fungal, or viral infections
- People who have participated in another clinical trial within the past 3 months
- People whom the trial investigators consider unsuitable for any other reason
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: HuiSheng Chen, Ph.D, The General Hospital of Northern Theater Command
Phone: +8624897511
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The changes of glycosylated hemoglobin, compared with baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.